Dr. Stephen Salloway on the Implications of FDA's Decision on Aducanumab

A decision from the FDA on whether to approve aducanumab as the first new treatment for Alzheimer's in the last 17 years is expected next month. What will it mean for the millions with early-stage disease if it is approved?

Dr. Stephen Salloway, director of the Memory and Aging Program and of Neurology at Butler Hospital and Professor of Psychiatry and Human Behavior and of Neurology at The Warren Alpert Medical School of Brown University, recently talked through the possibilities with Being Patient Alzheimer's.